- Evolus ( NASDAQ: EOLS ) is trading down ~13% after the company posted mixed results for the second quarter and full-year guidance that missed estimates.
- The company reaffirmed 2022 net revenue guidance of upper end of $143M to $150M vs. consensus of $150.27M.
- Q2 GAAP EPS was -$0.42 and missed estimates by $0.11.
- Revenue rose 42.5% Y/Y to $37.2M, but beat estimates by $0.55M, driven primarily by higher volumes and a slightly higher average selling price of Jeuveau.
- Evolus added 590 new customer accounts during the quarter.
- Operating expenses increased 18% Y/Y to $58.5M in the quarter.
- Cash at June 30 was $84.5M.
- The company said it remains on track to launch Nuceiva in Europe beginning in the third quarter of 2022.
For further details see:
Evolus down 13% on 2022 guidance below estimates, wider-than-expected Q2 loss